U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H24N6O2.C3H3F3O2
Molecular Weight 580.5577
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BELUMOSUDIL TRIFLUOROACETATE

SMILES

OC(=O)CC(F)(F)F.CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=C(C=CC=C3)C(NC4=CC=C5NN=CC5=C4)=N2

InChI

InChIKey=PBWWPJDQYJXRII-UHFFFAOYSA-N
InChI=1S/C26H24N6O2.C3H3F3O2/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22;4-3(5,6)1-2(7)8/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31);1H2,(H,7,8)

HIDE SMILES / InChI
Molecular Formula C3H3F3O2
Molecular Weight 128.0499
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C26H24N6O2
Molecular Weight 452.5078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://kadmon.com/research-development/pipeline/ http://en.pharmacodia.com/web/drug/1_1994.html

KD025 is an orally available, selective small molecule inhibitor of ROCK2 (Rho-associated coiled-coil kinase 2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. KD025 is the only ROCK2-specific inhibitor in the clinical trials. KD025 down-regulates the IL-17 and IL-21 secretion in human PBMCs, and leads to down-regulation of STAT3 phosphorylation, IRF4, and RORγt expression in CD4+ T cells. Kadmon Pharmaceuticals initiated phase II clinical trials of KD025 for the treatment of Graft-versus-host disease; Idiopathic pulmonary fibrosis; Plaque psoriasis.

CNS Activity

Originator

Approval Year

2021
470
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 60.0 nM [IC50]
Inhibitor
8297
Interleukin-21
3
Target ID: Q9HBE4
Gene ID: 59067.0
Gene Symbol: IL21
Target Organism: Homo sapiens (Human)
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
128.4 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32192179
5 mg/kg single, oral
dose: 5 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
KD-025 FREE BASE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
48.7 μg × min/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32192179
5 mg/kg single, oral
dose: 5 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
KD-025 FREE BASE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
353.4 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/32192179
5 mg/kg single, oral
dose: 5 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
KD-025 FREE BASE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
400 mg 2 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28389592
Page: p.3811
unhealthy
n = 7
Health Status: unhealthy
Condition: psoriasis
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/28389592
Page: p.3811
Disc. AE: ALT increased, AST increased...
AEs leading to
discontinuation/dose reduction:
ALT increased (33.3%)
AST increased (33.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/28389592
Page: p.3811
AEs

AEs

AESignificanceDosePopulation
ALT increased 33.3%
Disc. AE
400 mg 2 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28389592
Page: p.3811
unhealthy
n = 7
Health Status: unhealthy
Condition: psoriasis
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/28389592
Page: p.3811
AST increased 33.3%
Disc. AE
400 mg 2 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/28389592
Page: p.3811
unhealthy
n = 7
Health Status: unhealthy
Condition: psoriasis
Sex: M+F
Food Status: UNKNOWN
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/28389592
Page: p.3811
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P003AXB
https://www.1pchem.com/search?query=1P003AXB
AChemBlock
L13971
http://www.achemblock.com/catalogsearch/result/?q=L13971
AK Scientific
4050AH
https://aksci.com/item_detail.php?cat=4050AH
Ambeed
A255643
http://www.ambeed.com/search/Search.html?keyword=A255643
ApexBio Technology
A3825
https://www.apexbt.com/catalogsearch/result/?q=A3825
AstaTech
42507
http://astatechinc.com/CPSResult.php?CRNO=42507
Axon MedChem
2780
https://www.axonmedchem.com/product/2780
BLD Pharm
BD448309
http://www.bldpharm.com/search/Search.html?keyword=BD448309
Cayman Chemical
17055
http://www.caymanchem.com/app/template/Product.vm/catalog/17055
Chem Scene
CS-0776
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0776
ChemShuttle
152129
https://www.chemshuttle.com/catalogsearch/result/?q=152129
Combi-Blocks
QV-8526
http://www.combi-blocks.com/cgi-bin/find.cgi?QV-8526
Excenen
EX-A2314
http://www.excenen.com/searchresultlist.php?id=EX-A2314
KeyOrganics
AS-35230
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-35230
MedChem Express
HY-15307
https://www.medchemexpress.com/search.html?q=HY-15307&ft=&fa=&fp=
MolPort
MolPort-039-139-806
https://www.molport.com/shop/molecule-link/MolPort-039-139-806
MuseChem
I005432
https://www.musechem.com/product/I005432.html
Selleck Chemicals
S7936
http://www.selleckchem.com/search.html?searchDTO.searchParam=S7936
ShangHai Biochempartner
BCP15921
http://www.biochempartner.com/search_BCP15921
eMolecules
44811418
https://orderbb.emolecules.com/search/#?query=44811418
mcule
MCULE-6423720146
https://mcule.com/MCULE-6423720146/
PubMed

PubMed

TitleDatePubMed
Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.
2014 Nov 25
ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.
2016 Jul 19
Patents

Patents

WO2014055996A2
3

Sample Use Guides

In Vivo Use Guide
KD025 dose of 200 mg daily for 4 weeks
Route of Administration: Oral
In Vitro Use Guide
KD025 selectively inhibited ROCK2 with IC50 values ~60 nmol/L, but had little effect on ROCK1 enzymatic activity at concentrations up to 10 umol/L in a recombinant enzyme system
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:55:31 GMT 2023
Edited
by admin
on Sat Dec 16 15:55:31 GMT 2023
Record UNII
LL4OG4RZ5D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BELUMOSUDIL TRIFLUOROACETATE
Common Name English
ACETAMIDE, 2-(3-(4-(1H-INDAZOL-5-YLAMINO)-2-QUINAZOLINYL)PHENOXY)-N-(1-METHYLETHYL)-, 2,2,2-TRIFLUOROACETATE (1:1)
Systematic Name English
Code System Code Type Description
FDA UNII
LL4OG4RZ5D
Created by admin on Sat Dec 16 15:55:31 GMT 2023 , Edited by admin on Sat Dec 16 15:55:31 GMT 2023
PRIMARY
CAS
911417-96-4
Created by admin on Sat Dec 16 15:55:31 GMT 2023 , Edited by admin on Sat Dec 16 15:55:31 GMT 2023
NON-SPECIFIC STOICHIOMETRY
CAS
1243152-02-4
Created by admin on Sat Dec 16 15:55:31 GMT 2023 , Edited by admin on Sat Dec 16 15:55:31 GMT 2023
PRIMARY
PUBCHEM
154572893
Created by admin on Sat Dec 16 15:55:31 GMT 2023 , Edited by admin on Sat Dec 16 15:55:31 GMT 2023
PRIMARY
Related Record Type Details
Structure of Belumosudil
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of Belumosudil
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966